Serum amyloid A in polycystic ovary syndrome.

Huiqing Liu, Xingqi Meng, Jinyuan Wang, Yi Wei, Jinru Tang, Xiaocan Lei, Weiguo He, Suyun Li

Clinica chimica acta; international journal of clinical chemistry 2021 Jul

filter terms:

Polycystic ovary syndrome (PCOS), i.e., anovulation, hyperandrogenemia and polycystic ovary, is an endocrine-metabolic disease affecting reproductive aged women. Women with PCOS are likely to develop obesity, dyslipidemia, type 2 diabetes mellitus (T2DM) and cardiovascular diseases at a younger age. Despite high frequency and severe disease burden, the pathophysiological mechanisms of PCOS remain poorly defined and correspondingly have no therapeutic options. Emerging evidence has demonstrated that PCOS is accompanied with low-grade chronic inflammation and biomarkers thereof. Interestingly, serum amyloid A (SAA) has recently been identified as a potential marker of infection and inflammation and a number of studies have reported an association with PCOS. In this review, we explore the relationship between SAA and hyperandrogenemia, inflammation, obesity and insulin resistance, and provide convincing evidence for SAA as a potential inflammatory biomarker in PCOS. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Huiqing Liu, Xingqi Meng, Jinyuan Wang, Yi Wei, Jinru Tang, Xiaocan Lei, Weiguo He, Suyun Li. Serum amyloid A in polycystic ovary syndrome. Clinica chimica acta; international journal of clinical chemistry. 2021 Jul;518:151-155